Real-World Intravitreal Aflibercept 2 mg Treatment of Macular Oedema Secondary to Retinal Vein Occlusion in Italy: 24-Month Results from the AURIGA Observational Study.

ABSTRACT:

Introduction

This subgroup analysis of the global AURIGA study evaluated intravitreal aflibercept 2 mg (IVT-AFL) effectiveness and treatment patterns in routine practice in Italy in patients with macular oedema secondary to branch or central retinal vein occlusion (BRVO/CRVO).

Methods

AURIGA (NCT03161912) was a 24-month, prospective observational study in patients for whom IVT-AFL treatment had already been prescribed by their physician. All clinical decisions were according to physician discretion and local practice. Statistical analyses were descriptive only.

Results

In Italy, 152 treatment-naïve and 50 pretreated patients participated across 27 centres. Mean (95% confidence interval) change in visual acuity (VA) from baseline to month 12 in treatment-naïve patients

SUBMITTER: Grassi MO 

PROVIDER: S-EPMC12162111 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature